We’re looking for SAP developers to join our Global IT Department We’re looking for SAP developers to join our Global IT Department Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!
LastMile – improving through digital LastMile – improving through digital LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
Trailr2-cdh17-antibody-phase1-trial Trailr2-cdh17-antibody-phase1-trial Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
New Therapeutic Antibody Discovery Collaboration New Therapeutic Antibody Discovery Collaboration Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
Boehringer Ingelheim acquires Global Stem cell Technology Boehringer Ingelheim acquires Global Stem cell Technology Boehringer Ingelheim acquires Global Stem cell Technology, Belgian veterinary biotech company, to strengthen its stem cell capabilities in Animal Health
ArisGlobal acquires Boehringer Ingelheim technology ArisGlobal acquires Boehringer Ingelheim technology Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
inauguration_biopharmaceutical_production_facility_vienna inauguration_biopharmaceutical_production_facility_vienna The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
Monoclonal antibodies Boehringer Ingelheim and Invetx Monoclonal antibodies Boehringer Ingelheim and Invetx Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
IL-11 inhibitor antibody clinical development launched IL-11 inhibitor antibody clinical development launched Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Inauguration of new global center for veterinary vaccine R&D Inauguration of new global center for veterinary vaccine R&D Inauguration of a new global hi-tech centre for biological research and development in Lyon.
Retinal Health: Meet the Scientists Retinal Health: Meet the Scientists We aim to prevent, treat, and restore vision loss. Delve behind the lab to see our scientists spearheading research to address retinopathies.
Advancing health equity for rural doctors in Mexico Advancing health equity for rural doctors in Mexico Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location
Outside the lab…inside the family Outside the lab…inside the family We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
2019 performance 2019 performance Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Global language learning platform for our people Global language learning platform for our people One global learning platform for languages, countless opportunities to grow your career
Partnership Boehringer Ingelheim Lifebit health data Partnership Boehringer Ingelheim Lifebit health data Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
A global production network against supply shortages A global production network against supply shortages The production of medicines is a complex process. We use our global production network to respond to increasing demand.
Partnership for first-in-class cancer and CRM treatments Partnership for first-in-class cancer and CRM treatments Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
collaboration-Yale collaboration-Yale Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Clinical-phase2-trials-NASH-and-obesity Clinical-phase2-trials-NASH-and-obesity Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies